Abstract 1096
Background
OncotypeDX (ODX®) can enhance prediction of breast cancer recurrence, guiding adjuvant treatment options. However, the opportunity to access this test is not always possible. The aim of this study is to investigate the correlation between phenotypical tumor characteristics, quantitative classical immunohistochemistry (IHC) and recurrent score (RS) resulting from ODX®.
Methods
All breast cancer patients who underwent ODX® between 2014 and 2018 were retrospectively included in the study. The data selected for analysis were age, menopausal status, pathological and IHC features. IHC was performed with standardized quantitative methods. Dataset was split into two subsets (70% for training and 30% for internal validation). Logistic models were built with statistically significant features for predicting RS ≤ 25 or ≤ 20. An external validation set, provided by another center, was used to test reliability of prediction models.
Results
The internal dataset included 407 patients (Table) who underwent ODX®. Mean age was 53.7 (31-80) and 222 patients (54.55%) were > 50 years old. ODX® results showed: 67 patients (16.6%) between 0-10, 272 patients between 11-25 (66.8%) and 68 pts > 26 (16.6%). At the logistic regression analysis, RS score was significantly associated with ER (p = 0.004), PgR (p < 0.001), and Ki67% (p < 0.001) with the threshold equal to 25. Above patients with RS ≤ 25, the generalized linear regression resulted in a well calibrated model with an AUC of 92.2% (sensitivity 84.2%; specificity 80.1%). External validation set included 180 patients and confirmed the model performance with an AUC of 82.3% and good calibration. A nomogram predicting RS score ≤25 was generated.Table:
261P Tumor characteristics training set + internal test set
Training + internal test set – Tumor characteristics | ||
---|---|---|
Histological subtype classification | Invasive Ductal Carcinoma | 318 pts (78,1%) |
Invasive Lobular Carcinoma | 47 pts (11,5%) | |
Other | 42 pts (10,3%) | |
Grading | 1 | 28 pts (6.8%) |
2 | 268 pts (65,8%) | |
3 | 111 pts (27,3%) | |
pT | 1a | 3 pts (0,7%) |
1b | 38 pts (9,3%) | |
1c | 216 pts (53,1%) | |
2 | 143 pts (35,1%) | |
3 | 6 pts (1,5%) | |
4 | 1 pt (0,3%) | |
pN | 0 | 233 pts (57,2%) |
0i+ | 12 pts (3%) | |
1mic | 43 pts (10,6%) | |
1 | 108 pts (26,5%) | |
NA | 11 pts (2,7%) | |
Mean T diameter [cm] | 1.9 (Range 0,2-8,5) | |
Mean Sentinel Lymph Node (SLN) diameter [mm] | 1.7 (Range 0-40) | |
Mean Axillary Lymph Node (ALN) diameter [mm] | 0.8 (Range 0-25) | |
Mean N Ratio | 0.14 (0.00 – 1.00) | |
SLN involvement [n° of nodes] | 0 | 261 pts (64,1%) |
1 | 112 pts (27,5%) | |
2 | 24 pts (5,8%) | |
3 | 1 pt (0,2%) | |
NA | 9 pts (2,2%) | |
ALN involvement [n° of nodes] | 0 | 338 pts (83%) |
0i+ | 4 pts (1%) | |
1mic | 3 pts (0,7%) | |
1 | 31 pts (7,6%) | |
2 | 8 pts (2%) | |
3 | 5 pts (1,2%) | |
5 | 1 pt (0,2%) | |
NA | 17 pts (4,1%) | |
Multifocality | Yes | 97 pts (23,8%) |
No | 300 pts (73,7%) | |
NA | 10 pts (2.5%) | |
Multicentricity | Yes | 20 pts (4,9%) |
No | 376 pts (92,4%) | |
NA | 11 pts (2,7%) | |
PVI | Absent | 242 pts (59,4%) |
Focal | 51 pts (12,5%) | |
Moderate | 32 pts (7,8%) | |
Massive | 59 pts (14,5%) | |
NA | 23 pts (5,6%) | |
Mean ER expression | 87,9% (Range 1-100) | |
Mean PgR expression | 62.2% (Range 0-100) | |
Mean AR expression | 7.7% (Range 0-90) | |
Mean Ki67% expression | 29.8% (Range 0-90) | |
Her2 Expression | 0 | 187 pts (46%) |
1 | 112 pts (27,5%) | |
2 | 104 pts (25,5%) | |
NA | 4 pts (0,9%) | |
Fluorescence in situ hybridization (FISH) for HER-2 | Not determined | 300 pts (73,7%) |
Not amplificated | 100 pts (23,7%) | |
Undetermined | 1 pt (0,2%) | |
Equivocal | 1 pt (0,2%) |
Conclusions
Quantitative IHC presents a good correlation with RS score in patients with RS ≤ 25, also in external validation set. A nomogram for physician that enhances a cost/effectiveness clinical approach practice has been developed. Prospective clinical application will be tested in further studies.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Fabio Marazzi.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5792 - A novel PET parameter for cancer stem cell metabolism: early prediction of chemosensitivity to neoadjuvant chemotherapy in locally advanced breast cancer
Presenter: Chanwoo Kim
Session: Poster Display session 2
Resources:
Abstract
3728 - Using nodal ratio to predict recurrence in patients with 4 or more positive lymph nodes early stage breast cancer
Presenter: Besma Graja
Session: Poster Display session 2
Resources:
Abstract
3395 - Re-sentinel node biopsy for local recurrence after breast-conserving surgery
Presenter: Yuka Matsubara
Session: Poster Display session 2
Resources:
Abstract
4302 - Assessment of prognostic and therapeutic factors in men with breast cancer
Presenter: Daniel Herrero Rivera
Session: Poster Display session 2
Resources:
Abstract
4263 - Genomic Profiling of Chinese Breast Cancer Patients
Presenter: Zhonghua Tao
Session: Poster Display session 2
Resources:
Abstract
2406 - Genome copy number alteration burden represents predictor of response in long-term, never relapse exceptional responders of trastuzumab-treated HER2+ metastatic breast cancer
Presenter: Naomi Walsh
Session: Poster Display session 2
Resources:
Abstract
2575 - Next-generation DNA Sequencing (NGS) Results for Tumors From Phase 2 ABRAZO Study of Talazoparib After Platinum or Cytotoxic Non-Platinum Regimens in Patients (pts) With Advanced Breast Cancer (ABC) and Germline BRCA1/2 (gBRCA) Mutations
Presenter: Nicholas C. Turner
Session: Poster Display session 2
Resources:
Abstract
4499 - FGFR1 and CCND1 gene amplifications are associated with breast cancer resistance to aromatase inhibitors
Presenter: Evgeny Imyanitov
Session: Poster Display session 2
Resources:
Abstract
4110 - Clinicopathologic features of BRCA mutated breast cancer patients: Hacettepe Experience
Presenter: Sercan Aksoy
Session: Poster Display session 2
Resources:
Abstract
5203 - Novel fusion genes identified from matched primary and recurred breast cancers by RNA-sequencing
Presenter: Soojeong Choi
Session: Poster Display session 2
Resources:
Abstract